Bioelectrochemical analysis of neurodegeneration: Refocusing efforts
Source abstract
Abstract
Since 1970s, electrochemistry is enthusiastically used for studies of severe neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, or prion-associated transmissible spongiform encephalopathies, associated with the neuronal death in the brain. The existing electrochemical sensors can be used both for direct neurotransmitter analysis in the brain and for detection of both proteins/amyloid peptides and the extent of their aggregation/oligomerisation. However, these sensors' application in body fluids or certain brain areas of interest may be restricted by the presence of structurally or electrochemically related species interfering with electroanalysis. Thus, recent efforts are refocusing on bioelectroanalysis with the apatmer- and antibody-modified electrodes, enabling obtaining more specific, interference-free results that allow better correlations with the disease state. In this opinion, I consider these recent efforts aimed at deeper studies and better understanding of neurotransmitter and protein/peptide patterns linked to neurodegenerative disorders.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Electrochemical Analysis and Applications · Alzheimer's disease research and treatments · Biotin and Related Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (66)
Show source-provided references
1. Cooper · 1991
2. The worldwide costs of dementia 2015 and comparisons with 201010.1016/j.jalz.2016.07.150 ↗
3. https://www.who.int/news-room/fact-sheets/detail/dementia. Accessed 29 October 2021.
4. Lifelong management of amyloid-beta metabolism to prevent AD disease10.1056/NEJMe1207995 ↗
5. Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins10.1073/pnas.95.11.6448 ↗
6. The molecular pathology of Alzheimer's disease10.1016/0896-6273(91)90052-2 ↗
7. Alzheimer's disease: genes, proteins, and therapy10.1152/physrev.2001.81.2.741 ↗
8. Aggregation of microtubule binding repeats of Tau protein is promoted by Cu2+10.1021/acsomega.8b03595 ↗
9. S100A9-Driven amyloid-neuroinflammatory cascade in traumatic brain injury as a precursor state for Alzheimer's disease10.1038/s41598-018-31141-x ↗
10. Could an infection trigger Alzheimer's disease?10.1038/d41586-020-03084-9 ↗
11. Glycoproteomics in neurodegenerative diseases10.1002/mas.20221 ↗
12. microRNA dysregulation in neurodegenerative diseases: a systematic review10.1016/j.pneurobio.2019.101664 ↗
13. Hard target: understanding dopaminergic neurotransmission10.1016/0092-8674(94)90022-1 ↗
14. Fast-scan cyclic voltammetry: chemical sensing in the brain and beyond10.1021/acs.analchem.7b04732 ↗
15. Electrochemistry at the synapse10.1146/annurev-anchem-061318-115434 ↗
16. In vivo electrochemical sensors for neurochemicals: recent update10.1021/acssensors.9b01713 ↗
17. Electrochemical analysis of neurotransmitters10.1146/annurev-anchem-071114-040426 ↗
18. Electrochemical sensors and biosensors for determination of catecholamine neurotransmitters: a review10.1016/j.talanta.2016.06.066 ↗
19. Current advancement in electrochemical analysis of neurotransmitters in biological fluids10.1016/j.trac.2016.11.001 ↗
20. Electrochemical analysis of dopamine: perspectives of specific in vivo detection10.1016/j.electacta.2017.05.183 ↗
21. Nanomaterials-based electrochemical sensors for in vitro and in vivo analyses of neurotransmitters
22. Latest trends in electrochemical sensors for neurotransmitters: a review10.3390/s19092037 ↗
23. Electrochemical biosensing of dopamine neurotransmitter: a review10.3390/bios11060179 ↗
24. Nanoscale electrochemical sensor arrays: redox cycling amplification in dual-electrode systems10.1021/acs.accounts.6b00333 ↗
25. Electrodeposited gold on carbon-fiber microelectrodes for enhancing amperometric detection of dopamine release from pheochromocytoma cells10.1021/acs.analchem.8b02750 ↗
26. “Negative electrocatalysis”-based specific analysis of dopamine at basal plane Hopg in the presence of structurally related catecholamines10.1016/j.elecom.2018.02.019 ↗
27. Electrocatalytic discrimination between dopamine and norepinephrine at graphite and basal plane Hopg electrodes10.1002/elan.201700837 ↗
28. RNA aptamer-based electrochemical biosensor for selective and label-free analysis of dopamine10.1021/ac302134s ↗
29. Electrochemical label-free aptasensor for specific analysis of dopamine in serum in the presence of structurally related neurotransmitters10.1021/acs.analchem.5b04207 ↗
30. A DNA sequence obtained by replacement of the dopamine RNA aptamer bases is not an aptamer10.1016/j.bbrc.2017.05.134 ↗
31. Aptamer-field-effect transistors overcome Debye length limitations for small-molecule sensing10.1126/science.aao6750 ↗
32. Dopamine binding and analysis in undiluted human serum and blood by the RNA-aptamer electrode10.1021/acschemneuro.8b00616 ↗
33. A generalizable and noncovalent strategy for interfacing aptamers with a microelectrode for the selective sensing of neurotransmitters in vivo10.1002/anie.202008284 ↗
34. Amyloidosis: a clinico-pathophysiological synopsis10.1016/j.semcdb.2003.12.013 ↗
35. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies10.1046/j.1365-2796.2003.01262.x ↗
36. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution10.1007/s00109-003-0464-5 ↗
37. The amyloid phenomenon and its links with human disease10.1101/cshperspect.a023648 ↗
38. A rapid label-free electrochemical detection and kinetic study of Alzheimer's amyloid beta aggregation10.1021/ja052522q ↗
39. Direct electrochemical and AFM detection of amyloid-beta peptide aggregation on basal plane Hopg10.1039/C4NR02413C ↗
40. Electrochemical analysis Aβ42 peptide adsorption and aggregation on spectroscopic graphite10.1007/s00706-014-1362-y ↗
41. Electrochemical biosensors for biometal-protein interactions in neurodegenerative diseases10.1016/j.bios.2021.113035 ↗
42. Human serum albumin can regulate amyloid-β peptide fiber growth in the brain interstitium: implications for Alzheimer disease10.1074/jbc.C112.360800 ↗
43. Molecular bases of Alzheimer's disease and neurodegeneration: the role of neuroglia. Aging and disease10.14336/AD.2018.0201 ↗
44. Monitoring amyloid-β proteins aggregation based on label-free aptasensor10.1016/j.snb.2019.03.049 ↗
45. Amperometric aptasensor for amyloid-β oligomer detection by optimized stem-loop structures with an adjustable detection range10.1021/acssensors.9b01630 ↗
46. A novel electrochemical biosensor with molecularly imprinted polymers and aptamer-based sandwich assay for determining amyloid-β oligomer10.1016/j.jelechem.2020.114017 ↗
47. Electrochemical dual-aptamer biosensors based on nanostructured multielectrode arrays for the detection of neuronal biomarkers10.1039/D0NR03421E ↗
48. Electrochemical analysis of the fibrillation of Parkinson’s disease α-synuclein10.1039/C3AN01616A ↗
49. Alpha-synuclein oligomers—neurotoxic molecules in Parkinson's disease and other Lewy body disorders10.3389/fnins.2016.00408 ↗
50. The release of toxic oligomers from α-synuclein fibrils induces dysfunction in neuronal cells10.1038/s41467-021-21937-3 ↗
51. Aptasensors for the selective detection of alpha-synuclein oligomer by colorimetry, surface plasmon resonance and electrochemical impedance spectroscopy10.1016/j.snb.2017.01.171 ↗
52. Photoelectrochemical sensing of α-Synuclein based on a AuNPs/graphdiyne-modified electrode coupled with a nanoprobe10.1021/acsami.1c07617 ↗
53. Point-of-care platform for early diagnosis of Parkinson's disease10.1021/acsabm.0c01242 ↗
54. Biomarkers for Alzheimer's disease: current status and prospects for the future10.1111/joim.12816 ↗
55. Simultaneous quantification of Myelin Basic Protein and Tau proteins in cerebrospinal fluid and serum of Multiple Sclerosis patients using nanoimmunosensor10.1016/j.bios.2016.10.019 ↗
56. Development of a label-free electrochemical aptasensor for the detection of Tau381 and its preliminary application in AD and non-AD patients' sera10.3390/bios9030084 ↗
57. A novel electrochemical aptamer–antibody sandwich assay for the detection of tau-381 in human serum10.1039/C8AN00527C ↗
58. Femtomolar detection of thrombin in serum and cerebrospinal fluid via direct electrocatalysis of oxygen reduction by the covalent G4-hemin-aptamer complex10.1021/acsami.1c03784 ↗
59. Measurement of neuropeptide Y using aptamer-modified microelectrodes by electrochemical impedance spectroscopy10.1021/acs.analchem.0c03719 ↗
60. Cerebrospinal fluid biomarkers in neurodegenerative disorders10.2217/fnl-2018-0029 ↗
61. Plasma total prion protein as a potential biomarker for neurodegenerative dementia: diagnostic accuracy in the spectrum of prion diseases10.1111/nan.12573 ↗
62. Electrochemical aptasensor of cellular prion protein based on modified polypyrrole with redox dendrimers10.1016/j.bios.2013.12.051 ↗
63. Biomarkers of neurodegenerative disorders: how good are they?10.1038/sj.cr.7290235 ↗
64. Lifespan changes of the human brain in Alzheimer's disease10.1038/s41598-019-39809-8 ↗
65. Nucleic acid aptamers for neurodegenerative diseases10.1016/j.biochi.2017.10.026 ↗
66. From big data analysis to personalized medicine for all: challenges and opportunities10.1186/s12920-015-0108-y ↗